Drug intelligence / Profile preview

AEB2109

Development stage: Preclinical
Lead developer: Spyre Therapeutics
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Parenteral

Overview

AEB2109 is an engineered human enzyme therapy that degrades methionine, under development as an antineoplastic agent targeting the methionine dependence characteristic of certain cancers. It is classified as a new molecular entity and is being developed for oncologic indications such as solid tumors and hematological malignancies. The drug is being developed as part of Spyre Therapeutics' (formerly Aeglea Biotherapeutics) enzyme therapeutics program, aimed at targeting tumor biology through depletion of key amino acids required by cancer cells[1][10][13].

Beyond the preview

Go deeper on AEB2109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AEB2109.

Explore the full profile